Propanc Biopharma Enters Material Agreement, Sells Equity
Ticker: PPCB · Form: 8-K · Filed: Sep 27, 2024 · CIK: 1517681
| Field | Detail |
|---|---|
| Company | Propanc Biopharma, Inc. (PPCB) |
| Form Type | 8-K |
| Filed Date | Sep 27, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $33,000, $30,000, $0.0003, $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, financial-obligation
TL;DR
Propanc Biopharma signed a big deal and sold stock on 9/23.
AI Summary
Propanc Biopharma, Inc. announced on September 23, 2024, the entry into a material definitive agreement. This filing also details the creation of a direct financial obligation and unregistered sales of equity securities. The company is incorporated in Delaware and its fiscal year ends on June 30.
Why It Matters
This filing indicates Propanc Biopharma has entered into a significant agreement and has issued new equity, which could impact its financial structure and shareholder value.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and unregistered sales of equity, which can introduce financial obligations and dilution risks.
Key Players & Entities
- Propanc Biopharma, Inc. (company) — Registrant
- September 23, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 000-54878 (filing_id) — SEC File Number
- 33-0662986 (tax_id) — IRS Employer Identification Number
FAQ
What is the nature of the material definitive agreement entered into by Propanc Biopharma?
The filing states that Propanc Biopharma, Inc. entered into a material definitive agreement on September 23, 2024, but the specific details of this agreement are not provided in the excerpt.
What type of financial obligation was created by Propanc Biopharma?
The filing indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement of the registrant.
Were there any unregistered sales of equity securities by Propanc Biopharma?
Yes, the filing explicitly lists 'Unregistered Sales of Equity Securities' as an item of information.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on September 23, 2024.
What is Propanc Biopharma's state of incorporation and fiscal year end?
Propanc Biopharma, Inc. is incorporated in Delaware and its fiscal year ends on June 30.
Filing Stats: 1,091 words · 4 min read · ~4 pages · Grade level 12 · Accepted 2024-09-27 12:37:26
Key Financial Figures
- $33,000 — ny in the aggregate principal amount of $33,000 (the "Note"), for a purchase price of $
- $30,000 — 0 (the "Note"), for a purchase price of $30,000. The Company intends to use the net pro
- $0.0003 — tock at a price ("Conversion Price") of $0.0003 per share (the "Fixed Price"). Provided
- $0.0001 — then the Fixed Price shall be equal to $0.0001 per share. In the Event of Default (as
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex4-1.htm (EX-4.1) — 62KB
- ex10-1.htm (EX-10.1) — 76KB
- 0001493152-24-038462.txt ( ) — 380KB
- ppcb-20240923.xsd (EX-101.SCH) — 3KB
- ppcb-20240923_lab.xml (EX-101.LAB) — 33KB
- ppcb-20240923_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 26, 2024 PROPANC BIOPHARMA, INC. By: /s/ James Nathanielsz Name: James Nathanielsz Title: Chief Executive Officer and Chief Financial Officer